New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
07:36 EDTAZN, BMYBristol-Myers sees AstraZeneca deal closing in Q1
In December, the company announced plans to sell its global diabetes business that was part of its collaboration with AstraZeneca (AZN), enabling its continued evolution to a specialty care BioPharma company. Under terms of the agreement, AstraZeneca will make an upfront payment of $2.7B to Bristol-Myers Squibb (BMY), with potential regulatory- and sales-based milestone payments of up to $1.4B and will make royalty payments based on net sales through 2025. Of the $1.4B milestone payments, the company has already earned a $0.6B milestone payment with the recent approval of Farxiga in the U.S. that will be paid shortly after the closing of the transaction. In addition, AstraZeneca will make payments of up to $225M if and when certain assets are subsequently transferred. The transaction is expected to be accretive to non-GAAP EPS in the near-term and likely dilutive to non-GAAP EPS toward the latter part of the decade. The company anticipates that the transaction will close in 1Q14.
News For BMY;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
17:23 EDTBMYBristol-Myers gets FDA approval for Evotaz to treat HIV-1 infections
Subscribe for More Information
08:14 EDTBMYCelldex, Bristol-Myers initiate Phase 1/2 Varlilumab, Opdivo combination study
Subscribe for More Information
06:55 EDTAZNAstraZeneca announces four research collaborations for CRISPR
Subscribe for More Information
January 28, 2015
07:39 EDTAZNPfizer CEO says company not in need of big M&A deal, FT reports
Subscribe for More Information
January 27, 2015
12:54 EDTAZNBox, Inc. lands AstraZeneca contract to service 51,000 users, Re/code reports
Subscribe for More Information
07:37 EDTBMYBristol-Myers sees FY15 EPS $1.55-$1.70, consensus $1.71
Subscribe for More Information
07:31 EDTBMYBristol-Myers reports Q4 EPS 46c, consensus 41c
Subscribe for More Information
January 26, 2015
15:40 EDTBMYNotable companies reporting before tomorrow's open
Subscribe for More Information
15:24 EDTAZNTeva confirms U.S. approval of AstraZeneca's Nexium generic
Subscribe for More Information
11:29 EDTBMYBristol-Myers January weekly volatility increases into Q4 and outlook
Subscribe for More Information
January 22, 2015
08:49 EDTBMYBristol-Myers price target raised to $70 from $63 at SunTrust
Subscribe for More Information
January 21, 2015
12:30 EDTAZNGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
10:16 EDTBMY, AZNLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 20, 2015
16:34 EDTBMYBristol-Myers appoints Giovanni Caforio CEO
Bristol-Myers Squibb announced a number of leadership changes approved by its board of directors and effective at the close of the annual Shareholders’ Meeting on May. Giovanni Caforio, M.D. will become CEO of the company. Lamberto Andreotti will become executive chairman of the board of directors on May 5 and will continue to serve as chairman after his retirement on August 3. James M. Cornelius, 71, has chosen not to stand for re-election as non-executive chairman and will retire from the board. Togo D. West, Jr., 72, will become the lead independent director on the company’s board.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use